---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-045067"
form_type: "8-K"
ticker: "RIGL"
cik: "0001034842"
company_name: "RIGEL PHARMACEUTICALS INC"
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T10:30:54.236501+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Rigel Q1 net income $11.4M vs loss; revenue $53.3M (+68% YoY); 2025 outlook reaffirmed

## Summary
- Net product sales $43.6M up 68% YoY: TAVALISSE $28.5M (+35%), GAVRETO $9.0M, REZLIDHIA $6.1M (+25%).
- R289 granted FDA Orphan Drug (MDS) and Fast Track (lower-risk MDS); Phase 1b enrolling sixth dose level.
- Patent settlement with Annora allows generic TAVALISSE license in Q2 2032 or earlier; litigation terminated.
- Will not opt-in for ocadusertib; expects $40M non-cash revenue in Q2 from release of cost-share liability.
- 2025 outlook: total revenue $200-210M (excl. $40M one-time); positive net income expected for full year.

## SEC filing metadata
- accession: 0001104659-25-045067
- form_type: 8-K
- ticker: RIGL
- cik: 0001034842
- company_name: RIGEL PHARMACEUTICALS INC
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1034842/000110465925045067/0001104659-25-045067-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1034842/000110465925045067/tm2514128d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-045067
- JSON: https://secwatch.observer/filing/0001104659-25-045067.json
- Plain text: https://secwatch.observer/filing/0001104659-25-045067.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.